Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Long-Term Deferred Tax Non-Current Assets Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Anika Therapeutics (ANIK) Non-Current Debt (2020)

Historic Non-Current Debt for Anika Therapeutics (ANIK) over the last 5 years, with Q3 2020 value amounting to $25.0 million.

Anika Therapeutics' Non-Current Debt changed N/A to $25.0 million in Q3 2020 from the same period last year, while for Sep 2020 it was $25.0 million, marking a year-over-year change of. This contributed to the annual value of $8.0 million for FY2012, which is 1666.67% down from last year.
Anika Therapeutics' Non-Current Debt amounted to $25.0 million in Q3 2020.
Over the past 5 years, Anika Therapeutics' Non-Current Debt peaked at $50.0 million during Q2 2020, and registered a low of $25.0 million during Q3 2020.